Opioid agonist treatment and risk of mortality during opioid overdose public health emergency: population based retrospective cohort study LA Pearce, JE Min, M Piske, H Zhou, F Homayra, A Slaunwhite, M Irvine, ... Bmj 368, 2020 | 172 | 2020 |
Mortality among individuals accessing pharmacological treatment for opioid dependence in California, 2006–10 E Evans, L Li, J Min, D Huang, D Urada, L Liu, YI Hser, B Nosyk Addiction 110 (6), 996-1005, 2015 | 127 | 2015 |
Polydrug use and its association with drug treatment outcomes among primary heroin, methamphetamine, and cocaine users L Wang, JE Min, E Krebs, E Evans, D Huang, L Liu, YI Hser, B Nosyk International Journal of Drug Policy 49, 32-40, 2017 | 118 | 2017 |
HIV drug resistance detected during low-level viraemia is associated with subsequent virologic failure LC Swenson, JE Min, CK Woods, E Cai, JZ Li, JSG Montaner, ... Aids 28 (8), 1125-1134, 2014 | 111 | 2014 |
Performance of HIV-1 drug resistance testing at low-level viremia and its ability to predict future virologic outcomes and viral evolution in treatment-naive individuals A Gonzalez-Serna, JE Min, C Woods, D Chan, VD Lima, JSG Montaner, ... Clinical infectious diseases 58 (8), 1165-1173, 2014 | 100 | 2014 |
The cascade of care for opioid use disorder: a retrospective study in British Columbia, Canada M Piske, H Zhou, JE Min, N Hongdilokkul, LA Pearce, F Homayra, ... Addiction 115 (8), 1482-1493, 2020 | 85 | 2020 |
Gender differences in mortality among treated opioid dependent patients E Evans, A Kelleghan, L Li, J Min, D Huang, D Urada, YI Hser, B Nosyk Drug and alcohol dependence 155, 228-235, 2015 | 70 | 2015 |
The effects of opioid substitution treatment and highly active antiretroviral therapy on the cause-specific risk of mortality among HIV-positive people who inject drugs B Nosyk, JE Min, E Evans, L Li, L Liu, VD Lima, E Wood, JSG Montaner Clinical Infectious Diseases 61 (7), 1157-1165, 2015 | 64 | 2015 |
Gender inequities in quality of care among HIV-positive individuals initiating antiretroviral treatment in British Columbia, Canada (2000–2010) A Carter, J Eun Min, W Chau, VD Lima, M Kestler, N Pick, D Money, ... PloS one 9 (3), e92334, 2014 | 57 | 2014 |
Ending the HIV epidemic in the USA: an economic modelling study in six cities B Nosyk, X Zang, E Krebs, B Enns, JE Min, CN Behrends, C Del Rio, ... The Lancet HIV 7 (7), e491-e503, 2020 | 52 | 2020 |
Evaluation of risk mitigation measures for people with substance use disorders to address the dual public health crises of COVID-19 and overdose in British Columbia: a mixed … B Nosyk, A Slaunwhite, K Urbanoski, N Hongdilokkul, H Palis, K Lock, ... BMJ open 11 (6), e048353, 2021 | 50 | 2021 |
The causal effect of opioid substitution treatment on HAART medication refill adherence B Nosyk, JE Min, G Colley, VD Lima, B Yip, MJS Milloy, E Wood, ... Aids 29 (8), 965-973, 2015 | 49 | 2015 |
The impact of localized implementation: determining the cost-effectiveness of HIV prevention and care interventions across six United States cities E Krebs, X Zang, B Enns, JE Min, CN Behrends, C Del Rio, ... Aids 34 (3), 447-458, 2020 | 45 | 2020 |
Relative effects of antiretroviral therapy and harm reduction initiatives on HIV incidence in British Columbia, Canada, 1996–2013: a modelling study B Nosyk, X Zang, JE Min, E Krebs, VD Lima, MJ Milloy, J Shoveller, ... The lancet HIV 4 (7), e303-e310, 2017 | 44 | 2017 |
Inability to access health and social services associated with mental health among people who inject drugs in a Canadian setting L Wang, D Panagiotoglou, JE Min, K DeBeck, MJ Milloy, T Kerr, ... Drug and alcohol dependence 168, 22-29, 2016 | 44 | 2016 |
Characterizing retention in HAART as a recurrent event process: insights into ‘cascade churn’ B Nosyk, L Lourenço, JE Min, D Shopin, VD Lima, JSG Montaner, ... Aids 29 (13), 1681-1689, 2015 | 42 | 2015 |
HIV-1 disease progression during highly active antiretroviral therapy: an application using population-level data in British Columbia: 1996–2011 B Nosyk, J Min, VD Lima, B Yip, RS Hogg, JSG Montaner, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 63 (5), 653-659, 2013 | 35 | 2013 |
“Ending the epidemic” will not happen without addressing racial/ethnic disparities in the United States human immunodeficiency virus epidemic B Nosyk, E Krebs, X Zang, M Piske, B Enns, JE Min, CN Behrends, ... Clinical Infectious Diseases 71 (11), 2968-2971, 2020 | 34 | 2020 |
Cost-effectiveness of population-level expansion of highly active antiretroviral treatment for HIV in British Columbia, Canada: a modelling study B Nosyk, JE Min, VD Lima, RS Hogg, JSG Montaner The lancet HIV 2 (9), e393-e400, 2015 | 33 | 2015 |
Development and calibration of a dynamic HIV transmission model for 6 US cities X Zang, E Krebs, JE Min, A Pandya, BDL Marshall, BR Schackman, ... Medical Decision Making 40 (1), 3-16, 2020 | 31 | 2020 |